ClinicalTrials.gov
Cure8 trial brief
Why This Matters
This registry could collect real-world outcome data about hyperbaric oxygen therapy for many conditions that sometimes overlap with IBD care (Crohn’s disease, ulcerative colitis, pouchitis, rectovaginal fistula).
That data may help clinicians and patients understand how often HBOT is used for these indications and what quality-of-life changes are reported.
Who Should Pay Attention
Patients with Crohn’s disease or ulcerative colitis considering HBOT, clinicians who refer for or provide HBOT, researchers studying HBOT applications, and centers contributing registry data.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 4
Enrollment100 participants
Study statusNot_yet_recruiting
Source depthTrial registry record
What To Know
This is a ClinicalTrials.gov record for a multicenter registry study testing hyperbaric oxygen therapy (HBOT) across many “emerging indications,” including Crohn’s disease and ulcerative colitis.
The registry will collect standardized outcome data (including EQ-5D-5L quality-of-life measures) from patients receiving HBOT at typical treatment pressures (2.0–2.4 ATA for 90 minutes) and aggregate results in a central database. The trial is listed as an interventional Phase 4 study and is not yet recruiting.
Planned enrollment is about 100 participants across multiple conditions. Inclusion is broad: patients referred for HBOT for an emerging indication; common exclusions include standard contraindications to HBOT (untreated seizures, pneumothorax, significant pulmonary pathology, pregnancy).
Because this is a registry-style multicenter study, it is intended to gather observational outcome data and harmonize treatment and reporting practices across centers rather than to test a single randomized intervention. For IBD, the record lists both Crohn’s disease and ulcerative colitis among many other conditions being tracked.
If you are considering HBOT for IBD, this registry may expand understanding of how centers use HBOT and what patient-reported outcomes look like, but it does not by itself establish efficacy or replace disease-specific clinical trials.
Keep In Mind
This is a ClinicalTrials.gov trial record for a registry that is not yet recruiting. A registry gathers observational data across many sites and conditions; it does not constitute randomized evidence of benefit. The record lists many diverse conditions, and outcomes will be aggregated — findings for IBD-specific subgroups may be limited by enrollment numbers.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorJay C. Buckey Jr.
Trial IDNCT07240649
Study typeInterventional
Trial phasePhase 4
Enrollment100 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedSep 9, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Real world experience with granulocyte and monocyte adsorptive apheresis (ADACOLUMN®) in patients with refractory inflammatory bowel disease: a retrospective observational multicenter cohort study.
This study reports real-world outcomes with granulocyte and monocyte adsorptive apheresis (GMA) in patients with refractory IBD, showing steroid-free remission by week 14 in about one-third of patients and continued...
Who Still Needs Surgery? Defining the Modern Surgical Phenotype in Inflammatory Bowel Disease.
Surgery for IBD has become less common since modern biologic therapies, but a noticeable number of patients—especially with Crohn’s disease and poor nutrition—still progress to operations. Understanding who remains at...
Safety of Biologic and Immune-Modulating Agents in Breast Augmentation and Reconstruction
People with IBD often take biologics and may need or want implant-based breast surgery.